Ankündigung • Jul 10
Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026 Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026 Ankündigung • Apr 21
Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026 Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026 Reported Earnings • Jan 30
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Ankündigung • Jan 22
Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026 Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026 Buy Or Sell Opportunity • Nov 24
Now 21% overvalued Over the last 90 days, the stock has fallen 8.2% to ₹515. The fair value is estimated to be ₹426, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has grown by 14%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 27% in the next 2 years. Reported Earnings • Nov 01
Second quarter 2026 earnings released: EPS: ₹4.26 (vs ₹3.84 in 2Q 2025) Second quarter 2026 results: EPS: ₹4.26 (up from ₹3.84 in 2Q 2025). Revenue: ₹8.24b (up 20% from 2Q 2025). Net income: ₹1.02b (up 11% from 2Q 2025). Profit margin: 12% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Ankündigung • Oct 23
Indegene Limited to Report Q2, 2026 Results on Oct 30, 2025 Indegene Limited announced that they will report Q2, 2026 results on Oct 30, 2025 Board Change • Oct 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Non-Executive Independent Director Georgia Papathomas was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Aug 03
First quarter 2026 earnings released: EPS: ₹4.86 (vs ₹3.79 in 1Q 2025) First quarter 2026 results: EPS: ₹4.86 (up from ₹3.79 in 1Q 2025). Revenue: ₹7.61b (up 13% from 1Q 2025). Net income: ₹1.16b (up 33% from 1Q 2025). Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Ankündigung • Jul 24
Indegene Limited to Report Q1, 2026 Results on Jul 31, 2025 Indegene Limited announced that they will report Q1, 2026 results on Jul 31, 2025 Ankündigung • Jun 06
An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments. An undisclosed buyer agreed to acquire 10.19% stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments on June 3, 2025. The expected date of completion is June 06, 2025. Reported Earnings • Jun 01
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Ankündigung • May 29
Indegene Limited, Annual General Meeting, Jun 26, 2025 Indegene Limited, Annual General Meeting, Jun 26, 2025, at 16:30 Indian Standard Time. Reported Earnings • May 02
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. New Risk • Apr 30
New minor risk - Dividend sustainability The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Ankündigung • Apr 21
Indegene Limited to Report Q4, 2025 Results on Apr 28, 2025 Indegene Limited announced that they will report Q4, 2025 results on Apr 28, 2025 Ankündigung • Feb 25
Indegene Launches Cortex, A Fit-For-Purpose Generative Ai Platform Indegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement. Reported Earnings • Jan 31
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: ₹4.59 (up from ₹4.45 in 3Q 2024). Revenue: ₹7.58b (up 10% from 3Q 2024). Net income: ₹1.10b (up 11% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Recent Insider Transactions • Dec 29
Chairman & CEO recently bought ₹10m worth of stock On the 24th of December, Manish Gupta bought around 17k shares on-market at roughly ₹599 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹60m. This was Manish's only on-market trade for the last 12 months. Recent Insider Transactions • Dec 20
Non-Executive Director recently bought ₹60m worth of stock On the 17th of December, Rajesh Nair bought around 100k shares on-market at roughly ₹596 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹14m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Dec 07
Insider recently sold ₹13m worth of stock On the 5th of December, Viveksheel Ghai sold around 20k shares on-market at roughly ₹628 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹33m. Insiders have been net sellers, collectively disposing of ₹46m more than they bought in the last 12 months. Reported Earnings • Oct 29
Second quarter 2025 earnings released Second quarter 2025 results: EPS: ₹3.84. Net income: ₹917.0m (up ₹917.0m from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. Ankündigung • Oct 23
Indegene Limited to Report Q2, 2025 Results on Oct 28, 2024 Indegene Limited announced that they will report Q2, 2025 results on Oct 28, 2024 Recent Insider Transactions • Oct 01
Chief Financial Officer recently sold ₹33m worth of stock On the 27th of September, Suhas Prabhu sold around 50k shares on-market at roughly ₹669 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suhas' only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹675, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 46x in the Life Sciences industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹273 per share. Ankündigung • Aug 07
Indegene Limited, Annual General Meeting, Sep 06, 2024 Indegene Limited, Annual General Meeting, Sep 06, 2024, at 16:30 Indian Standard Time. Reported Earnings • Aug 02
First quarter 2025 earnings released: EPS: ₹3.79 (vs ₹3.09 in 1Q 2024) First quarter 2025 results: EPS: ₹3.79 (up from ₹3.09 in 1Q 2024). Revenue: ₹6.99b (up 9.9% from 1Q 2024). Net income: ₹877.0m (up 28% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Ankündigung • Jul 25
Indegene Limited to Report Q1, 2025 Results on Aug 01, 2024 Indegene Limited announced that they will report Q1, 2025 results on Aug 01, 2024 Ankündigung • May 23
Indegene Limited to Report Q4, 2024 Results on May 29, 2024 Indegene Limited announced that they will report Q4, 2024 results on May 29, 2024 
